• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    1/9/24 12:31:13 PM ET
    $ACET
    $AIMD
    $CUTR
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACET alert in real time by email

    Gainers

    • NexImmune (NASDAQ:NEXI) shares rose 97.5% to $14.95 during Tuesday's regular session. The company's market cap stands at $15.8 million.
    • Cutera (NASDAQ:CUTR) stock moved upwards by 36.47% to $4.49. The company's market cap stands at $89.8 million.
    • Adicet Bio (NASDAQ:ACET) stock rose 32.72% to $3.27. The company's market cap stands at $140.9 million.
    • Solid Biosciences (NASDAQ:SLDB) stock rose 30.42% to $7.76. The company's market cap stands at $156.5 million.
    • Galera Therapeutics (NASDAQ:GRTX) stock increased by 25.4% to $0.19. The market value of their outstanding shares is at $10.1 million.
    • cbdMD (AMEX:YCBD) stock increased by 22.47% to $0.9. The company's market cap stands at $2.6 million.

    Losers

    • Grifols (NASDAQ:GRFS) shares declined by 23.7% to $8.49 during Tuesday's regular session. The company's market cap stands at $5.7 billion.
    • Genprex (NASDAQ:GNPX) shares decreased by 13.6% to $0.24. The company's market cap stands at $14.3 million.
    • Ainos (NASDAQ:AIMD) shares decreased by 13.55% to $2.49. The company's market cap stands at $11.6 million.
    • PHAXIAM Therapeutics (NASDAQ:PHXM) stock decreased by 13.38% to $4.6. The market value of their outstanding shares is at $27.9 million.
    • Modular Medical (NASDAQ:MODD) stock fell 11.7% to $1.89. The market value of their outstanding shares is at $40.1 million.
    • Sharps Technology (NASDAQ:STSS) shares decreased by 11.56% to $0.35. The company's market cap stands at $5.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACET
    $AIMD
    $CUTR
    $GNPX

    CompanyDatePrice TargetRatingAnalyst
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    Solid Biosciences Inc.
    $SLDB
    6/26/2025$14.00Buy
    Citigroup
    Grifols S.A.
    $GRFS
    2/12/2025Overweight
    Morgan Stanley
    Solid Biosciences Inc.
    $SLDB
    1/8/2025$16.00Buy
    Truist
    Solid Biosciences Inc.
    $SLDB
    12/13/2024$16.00Outperform
    Wedbush
    Solid Biosciences Inc.
    $SLDB
    12/10/2024$15.00Mkt Outperform
    JMP Securities
    Adicet Bio Inc.
    $ACET
    9/30/2024$7.00Buy
    Guggenheim
    Adicet Bio Inc.
    $ACET
    9/11/2024Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ACET
    $AIMD
    $CUTR
    $GNPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Orbimed Advisors Llc bought $5,000,000 worth of shares (5,000,000 units at $1.00) (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    10/10/25 8:06:01 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $ACET
    $AIMD
    $CUTR
    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Perceptive Advisors Llc

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    3/11/26 4:00:03 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 7,168 shares, decreasing direct ownership by 25% to 21,692 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    2/27/26 6:34:18 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO and CFO Confer Ryan M. covered exercise/tax liability with 9,330 shares, decreasing direct ownership by 20% to 36,331 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    2/27/26 6:33:20 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $AIMD
    $CUTR
    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

    Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in 2H/2026 Achieved regulatory alignment with the FDA enabling outpatient dosing of prula-cel for lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients in ongoing and future clinical studies Regulatory filing for ADI‑212 in metastatic castration‑resistant prostate cancer (mCPRC) planned for 3Q/2026; enrollment expected to begin 4Q/2026 pending regulatory clearance Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell

    3/12/26 4:00:00 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

    - 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in muscle integrity, including stabilization and improvement in cardiac function (LVEF) observed after treatment with SGT-003 - - SGT-003 continued to demonstrate an encouraging safety profile and has been generally well tolerated in the 40 participants dosed as of March 11, 2026 - - SGT-003 is administered using a lower-burden, steroid-only prophylactic immunomodulation regimen - - The Company plans for additional meetings with the FDA in H1 2026 for gui

    3/11/26 1:01:00 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genprex to Participate at BIO Europe Spring 2026

    AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 23-25, 2026 in Lisbon, Portugal. In attendance will be Ryan Confer, President and Chief Executive Officer at Genprex and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. Throug

    3/10/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $AIMD
    $CUTR
    $GNPX
    SEC Filings

    View All

    Modular Medical Inc. filed SEC Form 8-K: Other Events

    8-K - Modular Medical, Inc. (0001074871) (Filer)

    3/13/26 4:00:48 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Adicet Bio Inc.

    S-8 - Adicet Bio, Inc. (0001720580) (Filer)

    3/12/26 5:20:46 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Adicet Bio Inc.

    S-3 - Adicet Bio, Inc. (0001720580) (Filer)

    3/12/26 5:17:44 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $AIMD
    $CUTR
    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Solid Biosciences with a new price target

    Needham initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

    12/4/25 8:48:04 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Solid Biosciences with a new price target

    Citigroup initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $14.00

    6/26/25 8:11:57 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Grifols, S.A.

    Morgan Stanley resumed coverage of Grifols, S.A. with a rating of Overweight

    2/12/25 9:09:54 AM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $AIMD
    $CUTR
    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

    SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 7:59:25 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACET
    $AIMD
    $CUTR
    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    Adicet Bio Appoints Michael Grissinger to the Board of Directors

    --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

    4/17/25 7:00:00 AM ET
    $ACET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    cbdMD, Inc. Announces Shareholder Approval of Automatic Conversion of Series A Preferred Stock and Other Results from Annual Meeting

    Charlotte, North Carolina--(Newsfile Corp. - April 10, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA) (the "Company" or "cbdMD") one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs and emerging THC-infused seltzer brand Herbal Oasis announced today that at the Company's annual meeting of shareholders held on April 10, 2025, that its Common Stock holders and 8% Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") holders approved the automatic conversion (the "Conversion") of shares of the Company's Preferred Stock into shares of the Comp

    4/10/25 5:57:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACET
    $AIMD
    $CUTR
    $GNPX
    Financials

    Live finance-specific insights

    View All

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance

    CHARLOTTE, N.C., Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with hemp derived THC beverage line Herbal Oasis today announced our financial results for the full fiscal year ended September 30, 2025. For fiscal year 2025, cbdMD delivered its third consecutive year of operational and financial improvement, reflecting disciplined cost management, focused execution, and continued investment in quality and science. The Company

    12/19/25 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary